Form 4: Fortress Biotech Director Receives Deferred Stock Grant

Fortress Biotech Director Jimmie Harvey was granted 27,322 restricted shares, deferred into units vesting over three years.

Summary

• Director Jimmie Harvey received a grant of 27,322 restricted shares of Fortress Biotech, Inc. common stock on January 1, 2026.
• The grant was made pursuant to the Issuer's 2013 Stock Incentive Plan, as amended.
• Harvey elected to defer 100% of these restricted shares into deferred share units under the Issuer's Deferred Compensation Plan for Directors.
• One-third of these deferred share units will vest annually on January 1, 2027, January 1, 2028, and January 1, 2029, contingent on continued service.
• Vested deferred shares will be delivered to Harvey in January of the year following termination of service, or earlier upon death or change in control of the issuer.
• Following this transaction, Harvey beneficially owns 146,704 shares, which includes 143,365 shares underlying deferred restricted stock units.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a neutral event in terms of immediate company performance but positive for long-term director alignment and retention. No negative operational or financial news is present.

Positives

• The grant of restricted stock aligns the director's interests with long-term shareholder value.
• The deferred compensation plan provides tax efficiency and retention incentives for the director.

Negatives

• No immediate cash inflow for the director from this specific grant due to the deferral election.

Risks

• Vesting of the deferred share units is subject to continued service, meaning the director must remain with the company to receive the shares.
• The ultimate value of the shares upon vesting is dependent on the future market price of Fortress Biotech, Inc. common stock.

Future Outlook

The grant of restricted stock and its deferral into share units indicates a long-term retention strategy for Director Jimmie Harvey, aligning his future compensation with the company's performance over the next three years.

Management Comments

• No direct management comments or quotes are provided in this Form 4 filing, which is typical for this document type.

Industry Context

This type of equity grant and deferral plan is a common practice in the biotechnology and broader corporate sectors for compensating non-employee directors, aiming to align their interests with long-term shareholder value and provide retention incentives. It reflects standard corporate governance practices for director remuneration.

Comparison to Industry Standards

• The grant of restricted stock and its deferral into share units with multi-year vesting is a standard compensation mechanism for directors in publicly traded companies, particularly within the biotech industry.
• Companies like Amgen (AMGN) or Gilead Sciences (GILD) often utilize similar equity-based compensation structures for their non-executive directors to foster long-term alignment and retention.
• The specific number of shares granted would typically be benchmarked against peer group compensation data, though such comparative data is not provided in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Aligns director's long-term interests with shareholder value through equity ownership.
• Director (Jimmie Harvey): Receives future equity compensation, subject to vesting and continued service, providing a long-term incentive.

Next Steps

• Continued service by Director Jimmie Harvey to meet vesting conditions for the deferred share units.
• Vesting of one-third of the deferred share units on January 1, 2027, January 1, 2028, and January 1, 2029.
• Delivery of vested deferred shares to the reporting person in January of the year following termination of service, or earlier upon death or change in control.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to a director as part of their compensation package, which is a standard corporate governance practice. It does not contain any information that would fundamentally alter the investment thesis for Fortress Biotech, Inc. The grant itself is a neutral event for immediate stock performance but supports long-term director alignment. Therefore, a 'hold' recommendation is appropriate as there's no new information to warrant a change in existing positions based solely on this filing.

Keywords

Fortress Biotech, FBIO, Jimmie Harvey, Restricted Stock, Deferred Compensation, Stock Incentive Plan, Director Compensation, SEC Form 4, Equity Grant